Internal Medicine, Hematology & Oncology · Albany, NY
NPI
1245564087
Since 2009
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
43 New Scotland Ave # 7
Albany, NY, 12208
Phone (518) 262-6696
Groups this clinician bills Medicare through
Medicare paid, 2024
$3.1M
158,421 services
Medicare patients, 2024
838
Average age 73
Drug cost, 2024
$8.8M
2,925 prescriptions
Company payments, 2025
$177
From 2 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Muhammad A Hussain was code J9144 (injection, daratumumab, 10 mg and hyaluronidase-fihj), 21,240 times for 19 patients. In total Muhammad A Hussain billed 158,421 services in 213 codes, and Medicare paid $3.1M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-06-28.
| Code |
|---|
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 21,240 | 19 | $38.72 | $823K |
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 17,850 | 27 | $0.28 | $5,024 |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 9,285 | 14 | $2.33 | $22K |
| J9025 Injection, azacitidine, 1 mg | Office | 9,165 | 12 | $0.28 | $2,589 |
| J1453 Injection, fosaprepitant, 1 mg | Office | 5,550 | 25 | $0.11 | $611 |
| J9271 Injection, pembrolizumab, 1 mg | Office | 5,400 | 13 | $44.58 | $241K |
| J9041 Injection, bortezomib, 0.1 mg | Office | 5,238 | 17 | $1.39 | $7,307 |
| J1568 Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 2,670 | 19 | $35.98 | $96K |
| J0897 Injection, denosumab, 1 mg | Office | 2,640 | 15 | $20.66 | $55K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 2,092 | 58 | $0.09 | $184 |
| J9312 Injection, rituximab, 10 mg | Office | 1,628 | 11 | $61.79 | $101K |
| 36415 Venipuncture Blood Collection | Office | 1,564 | 531 | $8.64 | $14K |
| 85025 Blood Count | Office | 1,533 | 541 | $7.61 | $12K |
| Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 1,450 | 13 | $0.10 | $141 |
| 80053 Clinical Chemistry | Office | 1,436 | 514 | $10.34 | $15K |
By year: 2022 $2.2M for 132,463 services; 2023 $2.0M for 143,454 services; 2024 $3.1M for 158,421 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 1,564 | 531 | $8.64 | $14K |
| 85025 Blood Count | 1,533 | 541 | $7.61 | $12K |
| 80053 Clinical Chemistry | 1,436 | 514 | $10.34 | $15K |
| 82784 Immunoassay | 1,040 | 201 | $9.11 | $9,478 |
| 83615 Clinical Chemistry | 933 | 356 | $5.92 | $5,522 |
| 83520 Immunoassay | 602 | 154 | $16.93 | $10K |
| 83735 Clinical Chemistry | 295 | 88 | $6.57 | $1,938 |
| 82728 Clinical Chemistry | 287 | 212 | $13.36 | $3,834 |
| 84100 Clinical Chemistry | 266 | 70 | $4.65 | $1,237 |
| 84550 Clinical Chemistry | 245 | 74 | $4.43 | $1,085 |
Medicare prescription drug claims, 2024
In 2024, the drug Muhammad A Hussain prescribed most often to Medicare patients was Acyclovir, with 474 prescriptions and refills. In total Muhammad A Hussain wrote 2,925 Medicare prescriptions that cost $8.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Acyclovir Generic | 474 | 549 | 88 | $5,508 |
| Eliquis Apixaban | 215 | 303 | 44 | $176K |
| Lenalidomide Generic | 133 | 133 | 20 | $1.5M |
| Allopurinol Generic | 104 | 123 | 35 | $498 |
| Prednisone Generic | 91 | 120 | 36 | $460 |
| Venclexta Venetoclax | 88 | 88 | 22 | $948K |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 72 | 117 | 23 | $448 |
| Hydroxyurea Generic | 69 | 132 | 25 | $1,787 |
| Warfarin Sodium Generic | 67 | 141 | 14 | $591 |
| Dexamethasone Generic | 67 | 120 | 30 | $1,791 |
| Levofloxacin Generic | 65 | 67 | 29 | $701 |
| Gabapentin Generic | 63 | 100 | 17 | $747 |
| Revlimid Lenalidomide | 58 | 58 | Under 11 | $871K |
| Pomalyst Pomalidomide | 56 | 56 | Under 11 | $1.3M |
| Ninlaro Ixazomib Citrate | 55 | 55 | Under 11 | $751K |
Brand drugs: 722 claims; generic drugs: 2,203 claims; opioid claims: 30.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Muhammad A Hussain $177 ($177 in general payments such as food, travel and fees) from 2 companies. The largest payer was Curonix LLC with $142.
| Company | Payments | Amount |
|---|---|---|
| Curonix LLC | 1 | $142 |
| AstraZeneca Pharmaceuticals LP AZN | 1 | $35.06 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.